Northern Trust
AARD

Northern Trust’s Aardvark Therapeutics AARD Stock Holding History

Northern Trust’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$334K Sell
88,599
-699
-0.8% -$7.25K ﹤0.01% 3766
2025
Q4 		$1.17M Buy
89,298
+32,101
+56% +$401K ﹤0.01% 3286
2025
Q3 		$760K Buy
57,197
+12,112
+27% +$137K ﹤0.01% 3512
2025
Q2 		$610K Buy
45,085
+31,084
+222% +$320K ﹤0.01% 3591
2025
Q1 		$105K Buy
+14,001
New +$157K ﹤0.01% 4105

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust's AARD Position: Q1 2026 in Review

Northern Trust reduced its Aardvark Therapeutics (AARD) stake by 0.78% in Q1 2026, selling an estimated $7.25K and leaving 88,599 shares worth $334K. The position accounts for ﹤0.01% of the portfolio, ranked #3766.

Northern Trust first reported a position in AARD in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.17M in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Northern Trust held 88,599 shares of Aardvark Therapeutics worth $334K as of Q1 2026.
  • Northern Trust sold 699 Aardvark Therapeutics shares in Q1 2026, an estimated $7.25K.
  • Aardvark Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3766 holding.
  • Northern Trust first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Northern Trust's Aardvark Therapeutics position peaked at $1.17M in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.